Background
The use of one’s own cells to treat tumors is typified by chimeric antigen receptor T cells (CAR T) therapy yet cells with anti-tumor properties being investigated continues to grow. We have previously proposed a new strategy using tumor-targeted mast cells (MC) obtained from autologous sources and demonstrated proof-of concept previously in vitro and in vivo.1–4
Methods
A human HER2/neu-specific IgE was used to arm human adipose-derived MC (ADMC) through the high affinity IgE receptor (FceRI) and intravenously (i.v.) injected into HER2/neu human tumor-cell bearing immunocompromised mice.
Results
It is shown for the first time that HER2/neu IgE–sensitized MC injected i.v. target and inhibit HER2/neu-positive tumors.
Conclusions
These studies provide further proof of concept that MC have anti-tumor properties and could possibly provide another strategy for developing adoptive cell transfer therapeutics for patients.
Acknowledgements
CLK was funded by NIH/NCI grant numbers 1R15CA246430 and 1R15CA283490, Specialized Center of Research grant and Pilot grant from UNC-Chapel Hill, Lineberger Cancer Center
References
Plotkin J, Kepley, CL. Human mast cells from adipose tissue target and induce apoptosis of breast cancer cells. Front. Immunol. February 8, 2019.
Fereydouni M, Kepley CL. Human tumor targeted cytotoxic mast cells for cancer immunotherapy. Front. Oncol. 2022 Apr 22;12:871390.
Elnaz Ahzini, Mohammad Fereydouni, Kepley CL. Identification and characterization of tunneling nanotubes involved in human mast cell FceRI-mediated apoptosis of cancer cells, Cancers 2022 Jun 14;14(12):2944.
Fereydouni M, Motaghed M, Ahani E, Kafri T, Dellinger K, Metcalfe DD and Kepley CL. Harnessing the anti-tumor mediators in mast cells as a new strategy for adoptive cell transfer for cancer. Front. Oncol. 2022;12:830199.